Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00413205 · ClinicalTrials.gov registry record · Phase 2
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 491
- Enrollment target
NCT00413205: Completed Phase 2 study, sponsored by Hoffmann-La Roche.
NCT00413205 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 491 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (269% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00413205, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 491 participants
- Enrollment target
Study Summary
This 2 arm study will investigate the efficacy, safety and tolerability of RAR Gamma versus placebo in ex-smokers with moderate or severe emphysema treated with optimal COPD therapy. Following optimization of COPD therapy (up to 6 weeks) patients will be randomized to receive either RAR Gamma (5mg) or placebo once daily using a 2:1 ratio (active:placebo), in addition to their standard therapy. Following the double-blind treatment period, patients will enter a 4-week follow-up period. The anticipated time on study period is 1-2 years, and the target sample size is 100-500 individuals.
Interventions
- DRUG Placebo
- DRUG RAR Gamma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 491 participants |
| Start Date | 2007-01 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
What the finished NCT00413205 record still lists
NCT00413205 is an interventional study that assigns participants to a tested intervention. The registered 491 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (269% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00413205 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00413205 about?
NCT00413205 is a clinical study titled "TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)". This 2 arm study will investigate the efficacy, safety and tolerability of RAR Gamma versus placebo in ex-smokers with moderate or severe emphysema treated with optimal COPD therapy. Following optimization of COPD therapy (up to 6 weeks) patients will be randomized to receive either RAR Gamma (5mg) ...
What is the current status of trial NCT00413205?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 491 participants. The study started on 2007-01. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00413205?
The interventions under investigation include: Placebo (DRUG), RAR Gamma (DRUG).
Who is sponsoring clinical trial NCT00413205?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00413205's enrollment target sits among peer trials
491 76th of 2000 higher than 1,925 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03418961 · 491 participants · Phase 3
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- NCT05861973 · 492 participants · NA
SMARTer Weight Loss Management
- NCT05908331 · 492 participants · NA
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
- NCT06152575 · 492 participants · Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia